From Hype to Pragmatism: How AI-Driven Drug Discovery Returns to the Essence of Medicine — 2023 Guangzhou Mini Forum on AI+Pharma Value Trends
In recent years, AI technology has demonstrated significant potential through its impressive performance in new drug development, attracting global attention from the pharmaceutical industry. This has sparked numerous discussions: Can AI-driven drug discovery truly resolve the longstanding challenges of traditional R&D? How can AI-enabled drug development shift from hype to pragmatism and return to the core essence of medicine creation? As AI moves from conceptual stages to practical application, deeper exploration is needed in more complex and challenging areas. On February 16, 2023, VCBeat, VB100, and Eggshell Research Institute will jointly host the 2023 Guangzhou Mini Forum on “Value Trends in AI-Driven Drug R&D” at Hejing Kesheng Plaza, Guangzhou International Bio Island.
The forum is expected to unveil the “2022 Industry Research Report on AI-Driven New Drug Development” in person for the first time, and will invite founders, co-founders, senior executives, industry researchers, and experts from investment institutions from multiple companies in the fields of artificial intelligence and new drug development, including Alibaba Cloud Computing Co., Ltd., Shenzhen Unknown Biotechnology Co., Ltd., Shenzhen Eaglet Pharma Co., Ltd., Shenzhen Capital Group Co., Ltd., Guangzhou Fermion Technology Co., Ltd., Xili Technology (Shenzhen) Co., Ltd., and Guangzhou Zhirui Pharmaceutical Technology Co., Ltd., to focus on the forefront of the industry.In-depth Dialogue and Cross-Industry Collaboration,Join Hands to Create New Opportunities for Win-Win Cooperation.
Event details are as follows. You are cordially invited to attend!
① Scan the QR code below or click the link to apply for a free ticket
Registration Link:https://vb100.mike-x.com/SEMIV
② Conference/Cooperation Inquiries: 17774983530 Ms. Wang (WeChat ID same as phone number)
February 16, 2023
13th Floor, Hejing Kesheng Plaza, No. 66, 68, and 70 Luoxuan Avenue, International Bio Island, Huangpu District, Guangzhou City
Forum Agenda | ||
Time | Agenda | Keynote Speaker |
13:00-14:00 | Sign-in | |
14:00-14:20 | Address | |
14:20-16:00 | Keynote Speech | Chen Xuanhe VCBeat Senior Researcher, VCBeat |
Shi Zejing Alibaba Cloud Computing Co., Ltd. Director of Healthcare Industry Architecture | ||
Tan Yan Shenzhen Xbiome Biotechnology Co., Ltd. Co-Founder,CEO | ||
Hu Tao Shenzhen Aigelin Pharmaceutical Co., Ltd. Director of Pharmacology | ||
16:00-16:10 | Tea Break | |
16:10-17:10 | Roundtable Discussion: Multi-Party Collaboration Accelerates the Clinical Implementation of New Drugs | Yu Jianlin Shenzhen GTJA Investment Group Co., Ltd. Managing Partner Chen Dong Guangzhou Fermion Technology Co., Ltd. Partner Li Yang Xili Technology(Shenzhen) Co., Ltd. Co-Founder and Executive Chairman Xu Yanli Guangzhou Zhirui Pharmaceutical Technology Co., Ltd. Senior Vice President |
VCBeat
VCBeat, founded in 2014, is China’s leading research and media platform for the healthcare industry. It is a third-party industrial service provider in the field of medical innovation, recognized by the National Health Commission, the National Healthcare Security Administration, and the United Front Work Department of the CPC Central Committee. Boasting China’s largest resource database for healthcare innovation and venture capital, VCBeat provides high-quality services—including media dissemination, industry research, brand events, as well as investment and financing matchmaking and industrial resource coordination—to enterprises, government bodies, industrial parks, and investment institutions.
VB100
VB100 is a business unit under Eggshell Technology, dedicated to serving governments, industrial parks, and large corporations. By organizing a diverse range of activities—including summits, competitions, forums, roadshows, seminars, and launch events—VB100 connects governments and large corporations with innovative enterprises, fostering industrial resource collaboration and driving industrial upgrading. Since its establishment, VB100 has expanded its presence to over 30 cities, including Beijing, Tianjin, Shanghai, Hangzhou, Wuxi, Shaoxing, Nanjing, Ningbo, Suzhou, Shenzhen, Guangzhou, Zhuhai, Wuhan, Zhengzhou, Xi’an, Chengdu, and Chongqing, hosting more than 300 events and conferences.
VCBeat
VCBeat Research Institute has consistently focused on innovation within the healthcare industry, which is undergoing transformation driven by a dual-engine model. It is committed to empowering corporate executives, investment decision-makers, and policymakers with intellectual support by leveraging its capabilities in data technology and in-depth industry research, thereby optimizing decision-making outcomes, accelerating industrial development, and serving as an industry accelerator. With seven years of accumulated industry resources in the healthcare sector, VCBeat maintains the world’s largest database of medical innovation enterprises, comprising approximately 70,000 companies, and has established deep connections with over 20,000 enterprises and institutions.
Hegesheng Plaza
Biopharmaceutical Innovation Industry Base,Guangzhou International Bio Island Business Landmark
Located at the core of Guangzhou International Bio Island, directly above two subway lines, Hexing Kesheng Plaza is a landmark-grade commercial office building on the island. It integrates seven key advantages: brand strength, transportation access, policy ecosystem, product quality, supporting facilities, and smart management.Kesheng Plaza stands proudly in Guangzhou International Bio Island—the heart of Guangzhou, a core city in the Greater Bay Area. As a national-level biotechnology industrial base and the future highland for biotech innovation in Guangzhou, the island offers convenient intercity transportation, strong industrial agglomeration effects, comprehensive supporting services, and preferential policies from Huangpu District.